Bharat Parenterals Ltd — Results, 28-07-2025: Result

The company's board has approved the financial results for the quarter. Standalone revenue was ₹94.37 Cr with PAT at ₹10 Cr. Consolidated revenue reached ₹116 Cr, with a net loss of ₹0.87 Cr. The 32nd Annual General Meeting is scheduled for September 26 to approve director appointments, including Mr. Alkesh Jayantilal Shah and re-appointment of Mr. Mukeshbhai Patel, plus new statutory auditors. Operations show Innoxel Lifesciences expanding its injectable pipeline, Varenyam Healthcare growing its domestic presence targeting ₹62-65 Cr revenue for FY26, and Varenyam Biolifesciences progressing on its ₹120-150 Cr facility for emerging markets.